Form 8-K - Current report:
SEC Accession No. 0001193125-25-028641
Filing Date
2025-02-18
Accepted
2025-02-18 16:23:42
Documents
14
Period of Report
2025-02-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d928043d8k.htm   iXBRL 8-K 32040
2 EX-10.1 d928043dex101.htm EX-10.1 37165
  Complete submission text file 0001193125-25-028641.txt   207357

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20250212.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20250212_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20250212_pre.xml EX-101.PRE 11251
16 EXTRACTED XBRL INSTANCE DOCUMENT d928043d8k_htm.xml XML 3643
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 25635258
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)